↓ Skip to main content

Oxycodone: a pharmacological and clinical review

Overview of attention for article published in Clinical and Translational Oncology, June 2007
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#37 of 1,348)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news
2 news outlets
twitter
2 X users
patent
3 patents
wikipedia
4 Wikipedia pages

Citations

dimensions_citation
113 Dimensions

Readers on

mendeley
236 Mendeley
Title
Oxycodone: a pharmacological and clinical review
Published in
Clinical and Translational Oncology, June 2007
DOI 10.1007/s12094-007-0057-9
Pubmed ID
Authors

A. Ordóñez Gallego, M. González Barón, E. Espinosa Arranz

Abstract

Oxycodone is a semi-synthetic opioid with an agonist activity on mu, kappa and delta receptors. Equivalence with regard to morphine is 1:2. Its effect commences one hour after administration and lasts for 12 h in the controlled-release formulation. Plasma halflife is 3-5 h (half that of morphine) and stable plasma levels are reached within 24 h (2-7 days for morphine). Oral bioavailability ranges from 60 to 87%, and plasma protein binding is 45%. Most of the drug is metabolised in the liver, while the rest is excreted by the kidney along with its metabolites. The two main metabolites are oxymorphone--which is also a very potent analgesic--and noroxycodone, a weak analgesic. Oxycodone metabolism is more predictable than that of morphine, and therefore titration is easier. Oxycodone has the same mechanism of action as other opioids: binding to a receptor, inhibition of adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability. These mechanisms also play a part in the onset of dependence and tolerance. The clinical efficacy of oxycodone is similar to that of morphine, with a ratio of 1/1.5-2 for the treatment of cancer pain. Long-term administration may be associated with less toxicity in comparison with morphine. In the future, both opioids could be used simultaneously at low doses to reduce toxicity. It does not appear that there are any differences between immediate and slow-release oxycodone, except their half-life is 3-4 h, and 12 h, respectively. In Spain, controlled-release oxycodone (OxyContin) is marketed as 10-, 20-, 40- or 80-mg tablets for b.i.d. administration. Tablets must be taken whole and must not be broken, chewed or crushed. There is no food interference. The initial dose is 10 mg b.i.d. for new treatments and no dose reduction is needed in the elderly or in cases of moderate hepatic or renal failure. Immediate-release oxycodone (OxyNorm) is also available in capsules and oral solution. Side effects are those common to opioids: mainly nausea, constipation and drowsiness. Vomiting, pruritus and dizziness are less common. The intensity of these side effects tends to decrease over the course of time. Oxycodone causes somewhat less nausea, hallucinations and pruritus than morphine.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 236 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Iran, Islamic Republic of 1 <1%
Chile 1 <1%
United States 1 <1%
Switzerland 1 <1%
Unknown 232 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 53 22%
Student > Master 32 14%
Other 23 10%
Researcher 21 9%
Student > Ph. D. Student 21 9%
Other 34 14%
Unknown 52 22%
Readers by discipline Count As %
Medicine and Dentistry 68 29%
Pharmacology, Toxicology and Pharmaceutical Science 26 11%
Biochemistry, Genetics and Molecular Biology 21 9%
Agricultural and Biological Sciences 14 6%
Chemistry 13 6%
Other 37 16%
Unknown 57 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2023.
All research outputs
#1,428,632
of 23,445,423 outputs
Outputs from Clinical and Translational Oncology
#37
of 1,348 outputs
Outputs of similar age
#2,570
of 69,732 outputs
Outputs of similar age from Clinical and Translational Oncology
#1
of 6 outputs
Altmetric has tracked 23,445,423 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,348 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 69,732 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them